Loading data for LXEO — first visit, this takes a few seconds.
Lexeo Therapeutics, Inc. (LXEO)
NasdaqGM: LXEO
· Real-Time Price · USD
4.70
-0.06 (-1.26%)
At close: Aug 31, 2026, 2:20 PM
The price, the headline numbers and the latest news, in one place.
Lexeo Therapeutics, Inc. (LXEO) Stock Price, Analysis & Data
No data available
| Bid | 3.32 |
| Market Cap | 386M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -87.3M |
| 1.47 | |
| -0.88 | |
| n/a | |
| -3.43 | |
| P/B (ttm) | 1.50 |
| P/S (ttm) | 0.00 |
| Earnings Date | Nov 4, 2026 |
| Ask | 5.76 |
| Volume | 420,463 |
| Avg. Volume (20D) | 937,498 |
| Open | 4.70 |
| Previous Close | 4.76 |
| Day's Range | 4.56 - 4.72 |
| 52-Week Range | 3.99 - 10.99 |
| Analyst | n/a |
| Price Target | n/a |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About LXEO
Lexeo Therapeutics, Inc., a clinical stage genetic medicine company, focuses on hereditary and acquired diseases with high unmet need in the United States. Its product pipeline comprises LX2006, an AAVrh10-based gene therapy candidate, which is in phase 1/2 clinical trial to treat friedreich ataxia cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate, which is in phase 1/2 to deliver a functional plakophilin-2 (PKP2) gene to cardiac mu...
Industry Biotechnology
Sector Healthcare
IPO Date Nov 3, 2023
Employees 63
Stock Exchange NasdaqGM
Ticker Symbol LXEO
Website https://www.lexeotx.com
Financial Performance
In 2025, Lexeo Therapeutics's revenue was 0, an increase of undefined% compared to the previous year's 0. Earnings were -99.96M, an increase of 1.66%.
Financial StatementsEarnings Surprise
Lexeo Therapeutics has released their quarterly earnings on Aug 12, 2026:
- Revenue of $0 misses estimates by $0, with NaN% YoY growth.
- EPS of -0.3 misses estimates by -0.02, with 55.88% YoY growth.
Lexeo Therapeutics, Inc. is scheduled to release its earnings on Nov 4, 2026, before market opens.
Analysts project revenue of ... Upgrade
Analysts project revenue of ... Upgrade
Page 1 of 2